BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “We have strong conviction in the potential for STAR-0215 to be the first-choice preventative therapy for HAE,” said Jill C. Milne, Chief Executive Officer at Astria Therapeutics. “Our final data from ...